Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:12 PM
Ignite Modification Date:
2025-12-24 @ 7:12 PM
NCT ID:
NCT03097003
Eligibility Criteria:
Inclusion Criteria:
\- Patients who meet ALL the following criteria can be enrolled:
* Male or female aged at least 18 years.
* With a diagnosis of moderate-to-severe chronic plaque psoriasis. As per Belgian National Institute for Health and Disability Insurance (NIHDI), moderate-to-severe plaque psoriasis in adult patients is defined by a Body Surface Area (BSA) \> 10% or aPsoriasis Area and Severity Index (PASI) \> 10.
* For whom the treating dermatologist has made the decision to commence apremilast treatment in accordance with the local label and reimbursement criteria
* Able to follow the instructions of the study.
* Having signed an Informed Consent Form (ICF)
Exclusion Criteria:
Patients who meet AT LEAST one of the following exclusion criteria will be excluded:
* Patients who have received apremilast \> 4 weeks prior to the enrolment visit.
* Women who are pregnant, breastfeeding or planning on becoming pregnant.
* Non-menopausal women who are not using an adequate contraception method.
* Patients with hypersensitivity to apremilast or to one of its excipients.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT03097003
Study Brief:
Protocol Section:
NCT03097003